Kestra Medical Technologies reported revenue of $28.64M and net income of -$38.84M for the quarter ended Apr 2026, up 66.2% year over year. This income statement covers 10 quarters of results from Jan 2024 through Apr 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||
| Revenue | 8.28M | 10.05M | 12.78M | 14.71M | 15.09M | 17.23M | 19.37M | 22.57M | 24.55M | 28.64M |
| Cost of RevenueCost of Rev | 7.40M | 8.66M | 8.58M | 8.88M | 8.54M | 9.60M | 10.52M | 11.14M | 11.65M | 12.96M |
| Gross Profit | 0.88M | 1.40M | 4.20M | 5.83M | 6.55M | 7.63M | 8.85M | 11.42M | 12.91M | 15.68M |
| Operating items | ||||||||||
| Research & DevelopmentR&D | 3.73M | 3.82M | 3.40M | 3.51M | 3.35M | 5.39M | 4.00M | 4.88M | 4.97M | 5.63M |
| Selling, General & AdministrativeSG&A | 17.09M | 17.93M | 19.23M | 21.45M | 23.80M | 50.46M | 33.73M | 38.30M | 42.70M | 49.39M |
| Operating ExpensesOpex | 20.83M | 21.75M | 22.63M | 24.96M | 27.15M | 55.84M | 37.73M | 43.18M | 47.67M | 55.03M |
| Operating IncomeOp. Inc | -19.95M | -20.35M | -18.43M | -19.13M | -20.60M | -48.21M | -28.88M | -31.75M | -34.77M | -39.34M |
| EBIT | -19.95M | -20.35M | -18.43M | -19.13M | -20.60M | -48.21M | -28.88M | -31.75M | -34.77M | -39.34M |
| Non-operating items | ||||||||||
| Non Operating Interest Expenses | 1.65M | 1.94M | 1.87M | 2.32M | 1.78M | 1.76M | 1.91M | 1.90M | 1.89M | 1.84M |
| Interest & Investment IncomeInt & Inv Inc | 0.04M | 0.88M | 0.63M | 1.66M | 2.17M | 1.80M | 2.16M | 2.23M | ||
| Other Non Operating IncomeOther Non Op Inc. | -0.01M | -0.03M | -0.05M | -0.04M | 0.01M | 4.79M | 2.83M | -0.89M | 0.36M | 0.32M |
| Net income details | ||||||||||
| EBT | -21.61M | -22.31M | -20.32M | -20.61M | -21.74M | -51.01M | -25.79M | -32.75M | -34.13M | -38.64M |
| Tax ProvisionsTaxes | 0.01M | -19.81M | 0.01M | 0.01M | 0.02M | -28.45M | 0.03M | 0.03M | 0.04M | 0.19M |
| Profit After TaxPAT | -21.62M | -22.28M | -20.32M | -20.62M | -21.76M | -51.11M | -25.83M | -32.78M | -34.17M | -38.84M |
| Income from Non-Controlling InterestsInc. Minority | -0.44M | -0.25M | -0.25M | |||||||
| Income from Continuing OperationsIncome (Continuing) | -21.62M | -2.50M | -20.32M | -20.62M | -21.76M | -22.56M | -25.83M | -32.78M | -34.17M | -38.84M |
| Consolidated Net IncomeConsol Net Inc. | -21.62M | -2.50M | -20.32M | -20.62M | -21.76M | -22.56M | -25.83M | -32.78M | -34.17M | -38.84M |
| Income towards Parent CompanyParent Net Inc | -21.62M | -2.50M | -20.32M | -20.62M | -21.76M | -22.56M | -25.83M | -32.78M | -34.17M | -38.84M |
| Preferred Dividend PaymentsPref Dividends | 1.81M | 1.99M | 2.38M | 3.32M | 3.32M | 3.29M | ||||
| Net Income towards Common StockholdersNet Income | -23.43M | -24.28M | -22.27M | -23.69M | -24.83M | -55.34M | -25.83M | -32.78M | -34.17M | -38.84M |
| Additional items | ||||||||||
| EPS (Basic) | -1.18 | -1.22 | -1.12 | -1.19 | -1.25 | -2.25 | -0.50 | -0.64 | -0.61 | -0.72 |
| EPS (Diluted) | -1.18 | -1.22 | -1.12 | -1.19 | -1.25 | -2.25 | -0.50 | -0.64 | -0.61 | -0.72 |
| Shares Outstanding | 19.89M | 19.89M | 19.89M | 19.89M | 19.89M | 24.58M | 51.30M | 51.38M | 55.85M | 54.18M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 19.89M | 19.89M | 19.89M | 19.89M | 19.89M | 24.58M | 51.30M | 51.38M | 55.85M | 54.18M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 19.89M | 19.91M | 19.91M | 19.91M | 19.89M | 24.58M | 51.35M | 51.45M | 58.35M | 58.38M |
| EBITDA | -19.95M | -20.35M | -18.43M | -19.13M | -20.60M | -48.21M | -28.88M | -31.75M | -34.77M | -39.34M |
| Interest ExpensesInt Expense | 1.65M | 1.94M | 1.87M | 2.32M | 1.78M | 1.76M | 1.91M | 1.90M | 1.89M | 1.84M |
| Tax Rate | -0.06% | 88.79% | -0.03% | -0.04% | -0.08% | 55.78% | -0.13% | -0.10% | -0.10% | -0.50% |